TD Cowen Keeps Their Hold Rating on GlaxoSmithKline (GSK)
TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...
FierceBiotech8d
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
Petri Dish: MIT's 'high-impact' initiative, GSK partners with local biotech
MIT launched a new life sciences initiative, a Woburn biotech started working with GSK and a local CFO joined a new Cambridge company.
Berenberg Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Berenberg Bank analyst Kerry Holford maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) on November 29 and set a price target ...